ArticleCancer immunology, immunotherapy : CII2021

Circulating PD-L1 levels change during bevacizumab-based treatment in recurrent glioma.

Maximilian J Mair et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.